ATE390425T1 - Xanthin-phosphodiesterase-v-hemmer polymorphe - Google Patents

Xanthin-phosphodiesterase-v-hemmer polymorphe

Info

Publication number: ATE390425T1
Authority: AT; Austria
Prior art keywords: polymorphos; inhibitor; xanthine phosphodiesterase; phosphodiesterase; xanthine
Prior art date: 2002-05-31

Application number

AT03756248T

Other languages

English (en)

Inventor

Vilas Dahanukar

Hoa Nguyen

Cecilia Orr

Fucheng Zhang

Ilia Zavialov

Kevin Klopfer

Jeffrey Skell

Albert Buchholz

Craig Boyle

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-31

Filing date

2003-05-30

Publication date

2008-04-15

2003-05-30 Application filed by Schering Corp filed Critical Schering Corp

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE390425T1 publication Critical patent/ATE390425T1/de

Links

LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
229940075420 xanthine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03756248T 2002-05-31 2003-05-30 Xanthin-phosphodiesterase-v-hemmer polymorphe ATE390425T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38448402P	2002-05-31	2002-05-31

Publications (1)

Publication Number	Publication Date
ATE390425T1 true ATE390425T1 (de)	2008-04-15

Family

ID=29712042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03756248T ATE390425T1 (de)	2002-05-31	2003-05-30	Xanthin-phosphodiesterase-v-hemmer polymorphe

Country Status (15)

Country	Link
US (1)	US7192962B2 (de)
EP (1)	EP1509524B1 (de)
JP (1)	JP2005529933A (de)
CN (1)	CN100384844C (de)
AR (1)	AR040233A1 (de)
AT (1)	ATE390425T1 (de)
AU (1)	AU2003249658A1 (de)
CA (1)	CA2486174A1 (de)
DE (1)	DE60319980T2 (de)
ES (1)	ES2299720T3 (de)
MX (1)	MXPA04011865A (de)
PE (1)	PE20040538A1 (de)
TW (1)	TW200404802A (de)
WO (1)	WO2003101991A1 (de)
ZA (1)	ZA200409644B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
WO2002092094A1 (en) *	2001-03-27	2002-11-21	Sumitomo Pharmaceuticals Co., Ltd.	Crystalline isoxazole derivative and medical preparation thereof
DE60307628T2 (de) *	2002-05-31	2007-08-09	Schering Corporation	Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
WO2005012303A1 (en) *	2003-07-31	2005-02-10	Schering Corporation	Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
KR20060101762A (ko) *	2003-11-21	2006-09-26	쉐링 코포레이션	포스포디에스테라제 ｖ 억제제 제형
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
JP2008520679A (ja) *	2004-11-18	2008-06-19	シェーリングコーポレイション	うっ血性心不全の処置のためにｐｄｅｖインヒビターを使用する方法
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
ATE451914T1 (de) *	2005-05-17	2010-01-15	Actelion Pharmaceuticals Ltd	Dispergierbare bosertan-tablette
CA2612917A1 (en) *	2005-06-23	2007-01-04	Schering Corporation	Rapidly absorbing oral formulations of pde5 inhibitors
WO2007070426A2 (en) *	2005-12-09	2007-06-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
WO2008139574A1 (ja) *	2007-04-27	2008-11-20	Ajinomoto Co., Inc.	ラクタム化合物の結晶形およびその製造方法
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
MX2023010642A (es)	2021-03-11	2023-11-28	Janssen Pharmaceutica Nv	Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
TW403740B (en) *	1997-06-10	2000-09-01	Novartis Ag	Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
PL191496B1 (pl) *	1997-07-02	2006-05-31	Merck & Co Inc	Odmiana polimorficzna 2-(R)-{1-(R) -[3,5-bis(trifluorometylo)-fenylo]etoksy} -3-(S)-(4-fluoro) fenylo-4-[3-(5-okso-1H,4H-1,2,4-triazolo)metylo] morfoliny, sposób jej wytwarzania, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6255316B1 (en) *	1997-08-27	2001-07-03	Novartis Animal Health Us, Inc.	Dicyclanil polymorphs and hydrates and their preparation
AR015190A1 (es)	1997-10-23	2001-04-18	Smithkline Beecham Corp	Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
FR2779726B1 (fr) *	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
DE60307628T2 (de) *	2002-05-31	2007-08-09	Schering Corporation	Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen

2003
- 2003-05-30 JP JP2004509682A patent/JP2005529933A/ja active Pending
- 2003-05-30 AR ARP030101922A patent/AR040233A1/es unknown
- 2003-05-30 ES ES03756248T patent/ES2299720T3/es not_active Expired - Lifetime
- 2003-05-30 PE PE2003000535A patent/PE20040538A1/es not_active Application Discontinuation
- 2003-05-30 EP EP03756248A patent/EP1509524B1/de not_active Expired - Lifetime
- 2003-05-30 MX MXPA04011865A patent/MXPA04011865A/es active IP Right Grant
- 2003-05-30 DE DE60319980T patent/DE60319980T2/de not_active Expired - Lifetime
- 2003-05-30 TW TW092114739A patent/TW200404802A/zh unknown
- 2003-05-30 WO PCT/US2003/016890 patent/WO2003101991A1/en not_active Ceased
- 2003-05-30 CA CA002486174A patent/CA2486174A1/en not_active Abandoned
- 2003-05-30 AU AU2003249658A patent/AU2003249658A1/en not_active Abandoned
- 2003-05-30 AT AT03756248T patent/ATE390425T1/de not_active IP Right Cessation
- 2003-05-30 CN CNB038124564A patent/CN100384844C/zh not_active Expired - Fee Related
- 2003-05-30 US US10/449,650 patent/US7192962B2/en not_active Expired - Fee Related
2004
- 2004-11-29 ZA ZA200409644A patent/ZA200409644B/en unknown

Also Published As

Publication number	Publication date
AU2003249658A1 (en)	2003-12-19
JP2005529933A (ja)	2005-10-06
US7192962B2 (en)	2007-03-20
MXPA04011865A (es)	2005-03-31
CA2486174A1 (en)	2003-12-11
AR040233A1 (es)	2005-03-23
EP1509524A1 (de)	2005-03-02
DE60319980D1 (en)	2008-05-08
EP1509524B1 (de)	2008-03-26
ES2299720T3 (es)	2008-06-01
PE20040538A1 (es)	2004-08-30
ZA200409644B (en)	2005-10-18
US20030232845A1 (en)	2003-12-18
DE60319980T2 (de)	2009-04-16
CN100384844C (zh)	2008-04-30
HK1068140A1 (en)	2005-04-22
CN1656097A (zh)	2005-08-17
WO2003101991A1 (en)	2003-12-11
TW200404802A (en)	2004-04-01

Legal Events

Date	Code	Title	Description
2008-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK1319003T3 (da)	2009-09-28	Xanthin-phosphodiesterase V-inhibitorer
DE60304911D1 (de)	2006-06-08	Xanthin-Derivate als DPP-IV-Inhibitoren
ATE395349T1 (de)	2008-05-15	Polycyclische guanin phosphodiesterase inhibitoren
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
NO2014008I2 (no)	2014-04-08	Linagliptin
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
IS7599A (is)	2004-12-15	Heterósýklískir kínasatálmar
ATE443054T1 (de)	2009-10-15	Cyano-pyrrolidine als dpp-iv inhibitoren
DK1549652T3 (da)	2009-02-23	Kondenserede azolpyrimidinderivater
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
DK1505963T3 (da)	2011-08-08	Hepatitis C-inhibitorer
DK1658291T3 (da)	2013-10-28	Substituerede 8-heteroaryl xanthiner
DE60319273D1 (de)	2008-04-03	Entzunderungsdüse
ATE529428T1 (de)	2011-11-15	Thioxanthinderivate als myeloperoxidaseinhibitoren
EP1546115A4 (de)	2010-08-04	Substituierte pyrimidine
NL1024643A1 (nl)	2004-05-03	Purineverbindingen en gebruik daarvan.
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
ATE450506T1 (de)	2009-12-15	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
DE60106252D1 (de)	2004-11-11	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe